Sign up to save your podcasts
Or
Share Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
In this episode, David M. Schuster, MD, FACR, highlights the recent FDA approval of flotufolastat F 18 (POSLUMA), a PSMA-PET imaging agent in prostate cancer. Schuster is a professor of radiology and imaging sciences and the director of the division of nuclear medicine and molecular imaging at Emory University School of Medicine in Atlanta, Georgia.
View all episodes
By Urology TimesIn this episode, David M. Schuster, MD, FACR, highlights the recent FDA approval of flotufolastat F 18 (POSLUMA), a PSMA-PET imaging agent in prostate cancer. Schuster is a professor of radiology and imaging sciences and the director of the division of nuclear medicine and molecular imaging at Emory University School of Medicine in Atlanta, Georgia.